CRISPR gene-editing continues to hit headlines regularly as a ground- breaking technology with many millions now flowing into companies seeking to exploit the technology in both therapeutic and agricultural fields. Unfortunately, the corresponding  IP landscape still has many issues to be resolved with possibility of divergence between Europe and the US.

This seminar will provide an overview of the CRISPR IP saga, discussion of considerations in relation to freedom-to-operate for use of the technology and an update on the lessons to be learnt from the IP issues which have inflicted major costs on those involved.

Event starts in
  • 01

  • 22

  • 06